EWTX241220C30000
- 5.00
- 0.000.00%
Edgewise Therapeutics Newsroom
Edgewise Therapeutics Analyst Ratings
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating
Edgewise Therapeutics Initiated at Outperform by Evercore ISI Group
Evercore Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $45
Edgewise Therapeutics Is Maintained at Outperform by Wedbush
Edgewise Therapeutics Analyst Ratings
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $42
Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $51
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating
Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $51
Edgewise Therapeutics Analyst Ratings
Piper Sandler Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)
Analysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX) and AnaptysBio (ANAB)
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $33
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $33
Wedbush Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $44
Edgewise Therapeutics Analyst Ratings
Leerink Partners Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $42
Buy Rating Affirmed on Edgewise Therapeutics' EDG-7500 for HCM Treatment Due to Promising Efficacy and Safety Profile
Edgewise Therapeutics Is Maintained at Buy by Truist Securities